There are currently 96 active clinical trials seeking participants for Glioblastoma research studies. The states with the highest number of trials for Glioblastoma participants are California, Ohio, New York and Texas.
Glioblastoma Remote Monitoring and Care - Research Protocol
Recruiting
The purpose of this research is to learn more about how what the Apple watch measures, in terms of walking data, heart rate, breathing rate, and sleep habits, relates to how participants feel. During the course of the treatment, the symptoms participants experience change, and whether the Apple watch can detect these changes. Ultimately, this knowledge is being used to design proactive tools and signatures that can predict complications or symptom changes before they happen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Glioblastoma, Venous Thromboembolism, Seizures
Methimazole in Patients With Progressive Glioblastoma
Recruiting
The purpose of this study is to test the effectiveness, safety, and tolerability of a drug called Methimazole. The investigational drug, Methimazole is not FDA approved for brain tumors, but it is used to treat thyroid illnesses. Different doses of Methimazole will be given to several study participants with glioblastoma. The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Glioblastoma, Glioma
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Recruiting
The purpose of this study is to test the safety and feasibility of recording brain activity within and around high-grade glioma tumors at the time of surgery. A small biopsy will be taken at the sites of the recordings.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: High Grade Glioma, Glioblastoma
Sacituzumab Govitecan in Recurrent Glioblastoma
Recruiting
This is an open-label single arm study. All patients will receive the investigational agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio +2 locations
Conditions: Glioblastoma
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Recruiting
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Glioblastoma, Gliosarcoma
GammaTile and Stupp in Newly Diagnosed GBM
Recruiting
In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local control or prolonged overall survival. As discussed above it seems unlikely that patient outcomes will be significantly improved with radiation dose escalation given at the time of the EBRT boost. However, as most failures are local, improving LC could potentially improve the OS of patients. To do this, we propose a shift in the traditional radiation paradigm.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: HonorHeath Scottsdale Osborn Medical Center, Scottsdale, Arizona +15 locations
Conditions: Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Recruiting
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +61 locations
Conditions: Glioblastoma
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Recruiting
A Dose Finding Study of \[177Lu\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/20/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +14 locations
Conditions: Glioblastoma
CARv3-TEAM-E T Cells in Glioblastoma
Recruiting
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Recruiting
Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. The survival for GBM has increased in the last decade but is still low with a median survival of 15-18 months. Recurrence after initial standard therapy, radiation therapy and chemotherapy with temozolomide, few options are available. Even with further therapy, median progression free survival at 6 months after first relapse (PFS-6) is only... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
05/15/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
Recruiting
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy. This study will take place in two parts: an initial dose escalation phase followed by a dose exploration phase. In the dose expansion phase, the maximum tolerated dose (MTD) of CART... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Glioblastoma
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Recruiting
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent Glioblastoma